On November 6, Moderna, Inc. rose 4.62% in Regular Trading, trading at $251.6589/share, with turnover of $507 million.

The move followed a quarterly earnings release that materially exceeded market expectations and an increase in the company’s full-year revenue forecast, supported by stronger overseas demand for its COVID vaccine.

Reported results showed quarterly EPS of $0.38, versus consensus expectations for a loss of about $1.10 to $1.26 per share, while third-quarter revenue reached about $1.31 billion, up 29% year over year and above expectations near $885 million. The company also raised its annual growth guidance to 15% to 25%. Earlier in the week, trading in Moderna, Inc. had been volatile as investors debated the commercialization timeline and valuation implications of its mRNA cancer vaccine platform, making the earnings surprise a direct catalyst for renewed risk appetite.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)